Baird lowered the firm’s price target on Denali Therapeutics (DNLI) to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the Tivi BLA was submitted and the commercial launch is on track for early 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
- Denali Therapeutics Advances Pipeline Amid Financial Loss
- Denali Therapeutics price target lowered to $30 from $32 at Wedbush
- Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright
- Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating